Surmodics Acquires Embolitech's Thrombectomy Technology Assets

May 14, 2018—Surmodics, Inc. announced that it has reached an agreement to acquire Embolitech's thrombectomy platform technology and related intellectual property, which have broad potential peripheral vascular applications. Under the agreement, Surmodics will pay $5 million up front and additional amounts related to various regulatory milestones.

The Embolitech platform is designed to remove difficult, organized blood clots. Surmodics will leverage its design, development, and manufacturing capabilities to advance the technology platform for a variety of peripheral and vascular applications.

According to Surmodics, the Embolitech technology may eliminate the need for the use of thrombolytics, reducing intensive care unit time and bleeding complications that significantly affect patient recovery and outcomes. In addition, the technology is anticipated to reduce procedure time and the need for multiple procedures, and it does not require any additional, external capital equipment.

Gary Ansel, MD, the Founder and Chief Medical Officer of Embolitech, commented in the announcement, “We are pleased to sign an agreement with Surmodics for this promising thrombus management platform that complements their current portfolio and aligns well with their focus on advancing therapies for peripheral artery disease.”